Standard BioTools Inc. (LAB)

Market Cap	185.77M
Revenue (ttm)	96.56M
Net Income (ttm)	-130.65M
Shares Out	78.38M
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	381,194
Open	2.31
Previous Close	2.32
Day's Range	2.30 - 2.44
52-Week Range	0.92 - 2.65
Beta	1.54
Analysts	n/a
Price Target	n/a
Earnings Date	May 9, 2023

About LAB

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Feb 10, 2011
• Employees: 523
• Stock Exchange: NASDAQ
• Ticker Symbol: LAB

Financial Performance

In 2022, LAB's revenue was $97.95 million, a decrease of -24.99% compared to the previous year's $130.58 million. Losses were -$190.10 million, 220.9% more than in 2021.